Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients
Information source: Mashhad University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hyperprolactinoma
Intervention: Curcumin (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Mashhad University of Medical Sciences Overall contact:
haleh rokni, proffessore assisstant, Phone: 00981082976, Email: roknih@mums.ac.ir
Summary
Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for
this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline. However, 50%
of Bromocriptin treated and 17% of Cabergoline treated patients are resistant to these
drugs. Curcumin is the main derivative of turmeric ,an old spice which is used frequently in
Indian and Iranian cuisine. It has been proved that curcumin can reduce mammotrope cells
proliferation and also intracellular hormone production. The purpose of this study is to
evaluate the effect of turmeric on prolactinoma patients.
Clinical Details
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: serum prolactin level
Secondary outcome: change in LH,FSH and estradiol from baseline
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- hyperprolactinemia
- microprolactinoma
Exclusion Criteria:
- pregnancy
- macroadenoma
- neurologic signs due to tumor
Locations and Contacts
haleh rokni, proffessore assisstant, Phone: 00981082976, Email: roknih@mums.ac.ir
Mashad University of Medical Sciences, Mashad, Khorasan Razavi, Iran, Islamic Republic of; Recruiting
haleh rokni, Phone: 00985118012976, Email: roknih@mums.ac.ir
Additional Information
Starting date: July 2011
Last updated: October 29, 2011
|
